Mersana Therapeutics, Inc. (MRSN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mersana Therapeutics, Inc. (“Mersana” or “the Company”) (NASDAQ: MRSN). Investors who purchased Mersana securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Mersana has violated federal securities laws.
Investigation Details:
On July 27, 2023, Mersana issued a press release “announc[ing] that the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary endpoint.” The press release stated that “UPLIFT was a single-arm clinical trial that enrolled platinum-resistant ovarian cancer patients with one to four prior treatment regimens. The primary endpoint for UPLIFT was the investigator-assessed objective response rate (ORR) in the NaPi2b-positive population. NaPi2b-positive status was defined by a tumor proportion score (TPS) of ≥75%.” On this news, Mersana’s stock price fell sharply during intraday trading on July 27, 2023.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Mersana securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]